All coverage
Pfizer shares hit record high with COVID-19 vaccine stocks on a tear
By Lewis Krauskopf & Sinead Carew
F.D.A. to Authorize Third Vaccine Dose for People With Weak Immune Systems (Published 2021)
By Sharon LaFraniere & Noah Mercer Weiland
What does full FDA approval of a vaccine do if it's already authorized for emergency use?
By Jennifer E. Girotto
COVID transmission among vaccinated, unvaccinated. What experts say.
By Adrianna Rodriguez
A Statistical Analysis of COVID-19 Breakthrough Infections and Deaths
By Kevin D. Dayaratna
Pfizer vax may be less effective against Delta variant: Mayo Clinic
By Ashley Collman
What's in a name? The term 'breakthrough infection' raises doubts about vaccines, but it shouldn't
By Sanjay Gupta
New data on coronavirus vaccine effectiveness against Delta raises concern among Biden administration
By Caitlin Owens
Pfizer, Moderna COVID vaccines face new safety probe in Europe over possible link to skin condition, 2 kidney disorders
By Kevin Dunleavy
FDA poised to OK 3rd vaccine dose for immunocompromised people
By Erika Edwards & Heidi Przybyla
CDC strengthens recommendation for pregnant women to get vaccinated against Covid-19
By Jacqueline Howard
EU looking into new possible side-effects of mRNA COVID-19 shots
By Pushkala Aripaka
Covid-19 vaccines: the contracts, prices and profits
By Julia Kollewe